The global digital therapeutics market size was estimated at USD 7.67 billion in 2024 and is projected to reach USD 32.5 billion by 2030, growing at a CAGR of 27.77% from 2025 to 2030. The market’s rapid growth is primarily attributed to the cost-effectiveness of digital health technologies for both healthcare providers and patients, along with the increasing penetration of smartphones and connected devices across developed and developing nations.
The growing preference for patient-centric care and the rising adoption of integrated healthcare systems are expected to further drive market expansion. Additionally, factors such as favorable reimbursement policies, the accelerated digital transformation of healthcare following the COVID-19 pandemic, early adoption of reimbursement frameworks, and the increasing prevalence of chronic diseases are significantly contributing to the market’s growth trajectory.
Digital therapeutics (DTx) represent a category of evidence-based, software-driven interventions specifically designed to prevent, manage, or treat medical conditions through clinically validated methodologies. Unlike general wellness or fitness applications, DTx solutions are developed with the primary goal of achieving measurable clinical outcomes. They empower patients to take an active role in managing their health while offering healthcare providers valuable data-driven insights to optimize treatment decisions and improve overall care quality.
Key Market Trends & Insights:
• North America dominated the global digital therapeutics industry, accounting for a revenue share of 40.11% in 2024. The region’s leadership position can be attributed to advanced healthcare infrastructure, high adoption of digital health technologies, and supportive government initiatives promoting digital healthcare solutions. The growing awareness about preventive healthcare and the increasing prevalence of chronic diseases have further contributed to the widespread adoption of digital therapeutics across the region.
• Within North America, the U.S. emerged as the leading market, holding the majority revenue share of 85.40% in 2024. The country’s dominance is driven by a strong presence of key industry players, rapid technological advancements, and favorable regulatory frameworks supporting digital health innovation. Additionally, the increasing use of mobile health applications, wearable devices, and software-based treatment platforms has accelerated market growth in the U.S.
• Based on application, the diabetes segment held the largest market share of 29.75% in 2024. This dominance is primarily due to the rising global burden of diabetes and the growing acceptance of digital solutions for effective disease management, real-time monitoring, and patient engagement. Digital therapeutics for diabetes offer patients improved control over their condition while enabling healthcare providers to track treatment progress remotely.
• In terms of end use, the patient segment accounted for the largest market share of 34.50% in 2024. The segment’s growth is fueled by the increasing preference for self-management tools, personalized care programs, and user-friendly digital platforms that empower patients to actively participate in their treatment journey. The convenience, accessibility, and effectiveness of these solutions have made digital therapeutics increasingly popular among patients seeking improved health outcomes and continuous care.
Order a free sample PDF of the Digital Therapeutics Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
• 2024 Market Size: USD 7.67 Billion
• 2030 Projected Market Size: USD 32.5 Billion
• CAGR (2025-2030): 27.77%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market
Key Companies & Market Share Insights:
The global digital therapeutics industry is characterized by intense competition and is largely dominated by a few well-established and recognized companies that hold a significant share of the market. These leading players continuously strive to strengthen their market position by focusing on innovation, expanding their product portfolios, and improving user engagement through advanced technology integration.
To maintain a competitive edge and broaden their global presence, companies are actively pursuing various strategic initiatives such as mergers, partnerships, collaborations, and acquisitions. These strategies enable them to access new markets, enhance their technological capabilities, and diversify their offerings across different therapeutic areas. Additionally, such alliances help accelerate product development, streamline regulatory approvals, and improve overall service delivery, further driving growth and innovation within the digital therapeutics industry.
Key Players
• OMADA HEALTH, INC.
• Welldoc, Inc.
• 2Morrow, Inc
• Livongo Health, Inc. (Teladoc Health, Inc.)
• Propeller Health (ResMed)
• Fitbit LLC
• Mango Health
• CANARY HEALTH
• Noom, Inc.
• Pear Therapeutics, Inc.
• Akili Interactive Labs, Inc.
• HYGIEIA
• DarioHealth Corp.
• BigHealth
• GAIA AG
• Limbix Health, Inc.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The digital therapeutics sector is poised for rapid expansion, spurred by increasing smartphone penetration, the affordability of digital health tools, and the shift toward patient-centric care and integrated healthcare systems. Growth is further supported by rising chronic disease incidence, favorable regulatory and reimbursement developments, and pandemic-driven adoption of digital care solutions. Key applications—such as diabetes management—are leading the trend, and North America continues to dominate regionally, while emerging markets are offering significant future growth opportunities.
